Disease · MONDO_0018352
Trials23
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 23
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00512096 | Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis | Phase 2 | 30 | 2010-12-08 | Penile Cancer | CISPLATIN, IFOSFAMIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT04231981 | Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) | Phase 2 | 18 | 2025-05-29 | Penile Cancer | RETIFANLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02541903 | Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma | Phase 2 | 8 | 2020-04-14 | Penile Squamous Cell Carcinoma (PSCC) | AFATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | Phase 2 | 6 | 2022-06-21 | Penile Squamous Cell Carcinoma | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | Phase 1 | 152 | Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma | CABOZANTINIB, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations | Phase 2 | 112 | Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer | PEMBROLIZUMAB, VORINOSTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | Phase 2 | 64 | Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Penile Squamous Cell Carcinoma | RIGOSERTIB | Its record names the disease | ClinicalTrials.gov | |
| NCT07518979 | EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer | Phase 2 | 60 | Penile Cancer | BECOTATUG VEDOTIN, PUCOTENLIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00210041 | Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma | Phase 2 | 50 | Genital Neoplasms, Male | CISPLATIN, GEMCITABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT07384416 | QL1706 Plus Lenvatinib in Previously Treated Penile Cancer | Phase 2 | 47 | Penile Cancer | LENVATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT07101822 | A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER | Phase 2 | 42 | Penile Cancer | CEMIPLIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02817958 | Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis | Phase 2 | 37 | Penile Cancer, Squamous Carcinoma | CISPLATIN, IFOSFAMIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT03943602 | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) | Phase 2 | 37 | Penile Squamous Cell Carcinoma | CABOZANTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT04224740 | Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer | Phase 2 | 37 | Penile Carcinoma | CARBOPLATIN, CISPLATIN, FLUOROURACIL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01728233 | Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis | Phase 2 | 32 | Penile Neoplasms, Carcinoma, Squamous Cell | DACOMITINIB ANHYDROUS | Its record names the disease | ClinicalTrials.gov | |
| NCT03686332 | PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study | Phase 2 | 32 | Penile Cancer | ATEZOLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03774901 | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma | Phase 2 | 32 | Penile Cancer, Penile Neoplasms, Penile Squamous Cell Carcinoma | AVELUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06104618 | Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis | Phase 2 | 28 | Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Unresectable Penile Squamous Cell Carcinoma | ENFORTUMAB VEDOTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06353906 | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer | Phase 2 | 27 | Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Penile Cancer, Penile Squamous Cell Carcinoma, Locally Advanced Penile Carcinoma | CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05526989 | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Phase 2 | 25 | Penile Carcinoma | DOSTARLIMAB, NIRAPARIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018352/trials